Autifony Therapeutics Limited   Report issue

For profit Phase 1 Phase 2
Founded: London United Kingdom (2011)

Organization Overview

First Clinical Trial
2014
NCT02315508
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Autifony Therapeutics Limited

Active Ingredients

Drugs in Phase 2 Trials (1)

aut00063 (3 trials)

Drugs in Phase 1 Trials (4)

aut00201 (2 trials)

aut00206 (3 trials)

ketamine (ketalar) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 2)

Hearing Loss (Phase 2)

Presbycusis (Phase 2)

Schizophrenia (Phase 1)

Tinnitus (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 5